Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
International Research Scientist Development Award (IRSDA)
Project Information in NIH RePORTER
Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
Principal Institution
University of North Carolina Chapel Hill
Principal Investigator(s) (PI)
Westmoreland, Katherine Douglas
Project Contact Information
Email: kawestmo@email.unc.edu
Year(s) Awarded
2019-2024
Country
Malawi
NIH Partners
NCI
Project Description
Burkitt lymphoma is the commonest cancer among children, adolescents, and young adults (AYA) in sub-Saharan Africa (SSA), and survival rates are dismal compared to resource-rich settings. This project focuses on improved understanding of chemotherapy pharmacokinetics (the movement of drugs within the body) and patient-reported health-related quality of life outcomes in this unique population, integrated within a rigorously conducted prospective clinical trial, to optimize treatment regimens and improve survival.
Related World Regions / Countries
Related Global Health Research Topics